Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ganetespib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 known ✓ | P08238 | 20/20 | 1.00 |
| ▸ | HSP90AA1 known ✓ | P07900 | 18/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 1/20 | 1.00 |
| ▸ | TRAP1 | Q12931 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganetespib SCHEMBL419750 | 1.00 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL29376128 | 1.00 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL501479 | 0.91 | HSP90AB1 (0.82) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL9924656 | 0.89 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL500866 | 0.89 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566976 | 0.89 | HSP90AB1 (0.79) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566979 | 0.89 | HSP90AB1 (0.79) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL25602985 | 0.88 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL419168 | 0.88 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL421109 | 0.88 | HSP90AB1 (0.78) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1854 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220054648-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | IMMUNOMEDICS, INC. | 2022-02-24 | — | — | US | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-111214664-B | Application of combination of USP2 and HSP90 inhibitor in inhibiting growth of ErbB2 positive breast cancer | 大连医科大学 | 2022-02-11 | — | — | CN | claimed |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | claimed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | HSP90AB1 1068/4885HSP90AA1 1462/4885HSP90B1 1315/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | HSP90AB1 233/4885HSP90AA1 291/4885HSP90B1 593/4885 |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | HSP90AB1 38/4885HSP90AA1 60/4885HSP90B1 27/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSP90AB1 1512/4885HSP90AA1 2073/4885HSP90B1 3145/4885 |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | PTH1R, SSTR4, MC4R | HSP90AB1 3546/4885HSP90AA1 3615/4885HSP90B1 3365/4885 |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | MSR1, TNFRSF9, TNFSF10 | HSP90AB1 1286/4885HSP90AA1 1849/4885HSP90B1 1081/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | HSP90AB1 2943/4885HSP90AA1 3328/4885HSP90B1 2973/4885 |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | CHEK1, ATR, MRE11 | HSP90AB1 2094/4885HSP90AA1 3097/4885HSP90B1 2166/4885 |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | PARP2, DOCK2, DYNLL2 | HSP90AB1 286/4885HSP90AA1 437/4885HSP90B1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.